Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial

RCT (n=2,309) found lanthanum was not superior to calcium carbonate for composite cardiovascular event rate when used for hyperphosphataemia in patients on haemodialysis (incidence rate 4.8 vs 4.3 per 100-person years, respectively, HR 1.11, 95%CI 0.88-1.41).

Journal of the American Medical Association